Acolyte and Ploughshare Innovations Agree Exclusive Licence For Adenylate Kinase
Acolyte Biomedica Ltd and Ploughshare Innovations Ltd have negotiated and agreed an exclusive global licence for the application of Adenylate Kinase (AK) in the fields of hygiene monitoring and clean-in-place monitoring of facilities, equipment and instruments used in clinical and veterinary practice. In addition, the parties have agreed a licence for the application of Adenylate Kinase in microbial diagnosis of animal tissues and fluids within veterinary practice.
AK technology was originally developed by the Defence Science and Technology Laboratory an agency of UK Ministry of Defence. Ploughshare Innovations have responsibility for managing the commercial exploitation of the technology under the AK Rapid® brand.
Unlike ATP, AK is present at constant levels in all eukaryotic and prokaryotic cells irrespective of the organism's metabolic state. The amplification of the conversion of ADP to ATP gives sensitivities up to 100 times those of standard ATP bioluminescence and up to 1 million times those of conventional optical measurements.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.